A Phase III, Multicenter, Rancomized Open-Label Study Evaluating the Efficacy and Safety of MPD3280A (Anti-PD-L1 Antibody)in Combination with Carboplatin + NAB-Paclitaxel for Chemotherapy-Naive Patients with Stage IV NSCLC
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
F. Hoffmann-La Roche Ltd
Start Date
August 1, 2015
End Date
December 30, 2020
Administered By
Duke Cancer Institute
Awarded By
F. Hoffmann-La Roche Ltd
Start Date
August 1, 2015
End Date
December 30, 2020